Capricor Therapeutics Inc (NASDAQ: CAPR), the biotechnology company, is focused on developing transformative exosome & cell-based therapies for treating and preventing a broad spectrum of diseases. In March 2021, the company announced that it is collaborating with Lonza for manufacturing and developing CAP-1002 to treat Duchenne muscular dystrophy, among other indications.
What’s ahead for CAPR?
This year, the company has also signed an exclusive agreement with the JHU, or Johns Hopkins University. The worldwide agreement includes engineered exosomes meant for therapeutics and vaccines. This is a part of its exosome technology portfolio. Additionally, Capricor Therapeutics Inc has also initiated significant IND-enabling studies directed at exosome-mRNA multivalent for the popular and much talked about SARS-CoV-2 vaccine. Meanwhile, JHU’s non-exclusive license to serology tests has also been granted, confirming SARS-CoV-2 vaccines activity.
Anticipations for the months ahead
In the times ahead, the company plans to present on SARS-CoV-2 vaccination delivery abstract at the 2021 Annual Meeting of the International Society for Extracellular Vesicles (ISEV). In addition, last month, the company had presented at the annual meeting of PPMD.
The company is also seeking FDA’s time for getting CAP-1002 approved for DMD. In the third quarter, Capricor Therapeutics Inc shall be announcing the next steps for the same. In Q3-2021, it has also planned to file IND for exosome-mRNA vaccine for its product candidate, given that it gets a go-ahead regulatory approval.
In Q1-2021, Capricor Therapeutics Inc incurred about $5.2 million of net loss, which can be translated as $0.23 per share. This compares with the net loss of $0.30 per share, or around $2.1 million in the previous year’s first quarter.
The company had around $41.9 million cash and cash equivalents until March 31, 2021, compared with around $32.7 million as of December 31, 2020.